This guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for prescription drugs. The disclosure of the product name in promotional labeling and advertisements is important for proper identification and to ensure safe and effective use. This guidance also articulates the circumstances under which FDA intends to refrain from taking enforcement action regarding these requirements. We believe that following this guidance will allow for appropriate advertising and promotion without presenting any public health risk to patients.
News & Trends
Procurar
Recentes
- EMVO Systems Updates | May 2026
- EU agrees to simplify AI rules to boost innovation and ban ‘nudification’ apps to protect citizens
- Formação DIGITAL PROMO REVIEW : ” Formação muito interativa , bem estruturada e com elevada partilha de casos práticos “
- Best Practice Guidance for the Submission of Technical Documentation under Annex II and III of Medical Device Regulation
- COMMISSION IMPLEMENTING REGULATION laying down certain uniform quality management and procedural requirements for the conformity assessment activities carried out by a notified body designated
- MASTER COURSE SUPLEMENTOS ALIMENTARES : “Evento muito bem organizado, conduzido e menistrado “
- Guidelines on the best practices for the traceability of medicines in hospital settings
- MDCG 2021-12 Rev.2 FAQ on the European Medical Device Nomenclature (EMDN) Revision 2 – April 2026

